Study of SPG302 in Adults With Schizophrenia

Description

This Phase 2 study described herein will evaluate the safety, efficacy, tolerability, and pharmacodynamics of SPG302 in adults with a primary diagnosis of schizophrenia.

Conditions

Schizophrenia

Talk to us

Study Overview

On this page

Study Details

Study overview

This Phase 2 study described herein will evaluate the safety, efficacy, tolerability, and pharmacodynamics of SPG302 in adults with a primary diagnosis of schizophrenia.

A Randomized, Placebo-controlled, Double-blind Phase 2 Study to Assess the Efficacy, Safety, Tolerability, and Pharmacodynamics of SPG302 in Adult Participants Diagnosed With Schizophrenia

Study of SPG302 in Adults With Schizophrenia

Condition
Schizophrenia
Intervention / Treatment

-

Contacts and Locations

Garden Grove

CenExel CNS, Garden Grove, California, United States, 92845

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age 18-65
  • * Primary diagnosis of schizophrenia
  • * Clinical laboratory values within normal range or \< 1.5 times ULN
  • * Currently prescribed only one antipsychotic medication, with stable dose for at least 4 weeks
  • * Able and willing to provide written informed consent
  • * Any physical or psychological condition that prohibits study completion
  • * Known cardiac disease
  • * Active or history of malignancy in the past 5 years
  • * History of clinically significant CNS event or diagnosis in the past 5 years.
  • * Receipt of investigational products within 30 days
  • * Blood donation within 30 days

Ages Eligible for Study

18 Years to 65 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Spinogenix,

Rebecca Ho, MD, PRINCIPAL_INVESTIGATOR, Multidisciplinary Alfred Psychiatry Research Centre (MAPrc)

Judith Hope, MD, PRINCIPAL_INVESTIGATOR, Box Hill

Study Record Dates

2025-10